Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. The purpose of the extension cohort is to further describe the safety and efficacy for the ACP-L dosing schedule versus ACP with additional data. After completion of the primary analysis, the study may eventually transition to an open-label extension (OLE) or long-term extension (LTE) phase during which participants will have the option to continue their assigned treatment.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Southern Cancer Center, PC | Mobile, Alabama, United States | — |
| Arizona Oncology Associates | Tucson, Arizona, United States | — |
| City of Hope | Duarte, California, United States | — |
| Cedars Sinai Medical Center | Los Angeles, California, United States | — |
| University of California Irvine | Orange, California, United States | — |
| Rocky Mountain Cancer Centers | Colorado Springs, Colorado, United States | — |
| Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center | Fort Lauderdale, Florida, United States | — |
| University Cancer And Blood Center LLC | Athens, Georgia, United States | — |
| University of Mississippi Medical Center | Jackson, Mississippi, United States | — |
| Nebraska Cancer Specialists | Grand Island, Nebraska, United States | — |
| Astera Cancer Care | East Brunswick, New Jersey, United States | — |
| TriHealth Network | Cincinnati, Ohio, United States | — |
+ 237 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.